Programme
### Sunday, June 18th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td>Registration</td>
</tr>
<tr>
<td>15:30</td>
<td><strong>Plenary Room</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Session I: The Young Pharmacologists Committees: Voice of the Future</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Dr. Miguel Romero (Spain) &amp; Dña. Mariella Ramos (Spain)</td>
</tr>
<tr>
<td></td>
<td>Young Pharmacologists Committee of the Spanish Society of Pharmacology (SEF). Patrice Gomes (Spain)</td>
</tr>
<tr>
<td></td>
<td>What do you want Young Pharmacologists Committee to do for you? Aida Collado (Spain)</td>
</tr>
<tr>
<td>16:30</td>
<td><strong>Session II: Orientation Seminar on Academic Career for Young Doctors</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Dr. Miguel Romero (Spain) &amp; Dr. Concha Peiró (Spain)</td>
</tr>
<tr>
<td></td>
<td>The pre-doctoral stage: how to prepare a good CV from the start. Sergio Montserrat-de la Paz (Spain)</td>
</tr>
<tr>
<td></td>
<td>How to be a post-doc and not die trying. Tania Romacho (Spain)</td>
</tr>
<tr>
<td></td>
<td>Climbing the ladder: career expectations versus academic reality. Eduardo Oliver (Spain)</td>
</tr>
<tr>
<td>17:30</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>18:00</td>
<td>Plenary Lecture- Role of the endocannabinoid system in food-induced addictive-like behavior, Rafael Maldonado (Spain)</td>
</tr>
<tr>
<td>19:00</td>
<td>Music and Reception</td>
</tr>
</tbody>
</table>

### Monday, June 19th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td><strong>Plenary Lecture-</strong> GPCR expression in health and disease identifies new therapeutic targets, Paul Insel (USA)</td>
</tr>
<tr>
<td>09:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td></td>
<td>Posters Session (P-1 to P-88)</td>
</tr>
<tr>
<td>11:00</td>
<td>Symposia</td>
</tr>
<tr>
<td>13:00</td>
<td><strong>Room:</strong> Gran Salon Mediterranea</td>
</tr>
<tr>
<td></td>
<td>S1. Pharmacology and toxicology of drug transporters: recent advances.</td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Ann Daly, Newcastle University (UK) &amp; Dan Antoine, University of Liverpool (UK)</td>
</tr>
<tr>
<td></td>
<td>Pharmacogenomics and epigenetic alteration of membrane transporters. Matthias Schwab (Germany)</td>
</tr>
<tr>
<td></td>
<td>PBPK modelling of drug transporters to facilitate individualized dose prediction. Aleksandra Galetin (UK)</td>
</tr>
<tr>
<td></td>
<td>ABC transporters in drug-induced liver injury. Jose Manautou (USA)</td>
</tr>
<tr>
<td></td>
<td>Scientific Perspective on the Evaluation of Transporter-based Drug-drug Interactions, Shiew-Mei Huang (USA)</td>
</tr>
</tbody>
</table>
### S2. Pain

**Chairs:** Jose Manuel Baeyens, *University of Granada (Spain)* & Esther Berrocoso, *University of Cadiz (Spain)*

- Pharmacological associations in pain. A real life scenario. Victor Mayoral (Spain)
- Implication of noradrenaline in pain and its emotional consequences. Esther Berrocoso (Spain)
- Sigma-1 receptor blockade unmask peripheral opioid analgesia. Jose Manuel Baeyens (Spain)
- Animal Models of Pain: Beyond the Evaluation of Reflexes. Enrique Portillo-Salido (Spain)

### S3. Ischaemia & Reperfusion

**Chairs:** Anna Planas, *IDIBAPS/CSIC (Spain)* & I. Mhairi Macrae, *University of Glasgow (UK)*

- Cerebrovascular pathology: novel pharmacological strategies. Mª Ángeles Moro (Spain)
- Novel therapies for acute ischemic stroke: from pharmacological neuroprotection to vasculoprotection. Sergio Amaro (Spain)
- Oxyxycyte: an intravenous oxygen carrier capable of diagnosing and treating acute ischaemic stroke. I. Mhairi Macrae (UK)
- Protection against myocardial reperfusion injury by targeting mitochondrial succinate dehydrogenase. Antonio Rodríguez (Spain)

### S4. G Protein-Coupled Receptors Pharmacology

**Chairs:** Ian McGrath, *University of Glasgow (UK)* & Leonardo Pardo, *Autonomous University of Barcelona (Spain)*

- The drug invention template: from "crafted round the natural hormone" to sculpted to fit the receptor. Ian McGrath, (UK)
- New approaches to modulate GPCRs. Leonardo Pardo (Spain)
- Optopharmacology: lighting up G protein-coupled receptors. Victor Fernández-Dueñas (Spain)
- GPCR Heterodimers: What are they good for and how do they work? Peter McCormick (UK)

### S5. Cardiovascular and smooth muscle pharmacology

**Chairs:** Juan Tamargo, *University Complutense of Madrid (Spain)* & Mª Pilar D’Ocon, *Valencia University (Spain)*

- New drugs in the treatment of heart failure: hope or hype? Juan Tamargo (Spain)
- Novel mediators of inflammation in vascular damage in hypertension. Ana Mª Briones (Spain)
- Drugs for pulmonary hypertension: old stories of partial success, partial failure and new perspectives. Francisco Pérez (Spain)
- Pleiotropic actions of Losartan metabolites in hypertension. Guillermo Zalba (Spain)

### S6. Natural Products in Pharmacology

**Chairs:** Salvador Fudio, *Pharmamar (Spain)* & Rafael de la Torre, *IMIM (Spain)*

- Quality of Herbal Medicinal Products: contribution of the European Pharmacopoeia. Salvador Cañigueral (Spain)
- Flavonoids in the treatment of mental disorders. Rafael de la Torre (Spain)
- Marine derived medicines for the treatment of cancer: the experience of PharmaMar. Salvador Fudio (Spain)
- Development of neuroprotective therapies with phytocannabinoids for neurodegenerative disorders. Javier Fernández (Spain)

### Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-14:30</td>
<td>Lunch</td>
</tr>
<tr>
<td>14:30-16:30</td>
<td>Symposia</td>
</tr>
<tr>
<td>16:30-17:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>17:00</td>
<td>Selected Posters for oral presentation</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
</tr>
<tr>
<td>-------</td>
<td>---------------------------------------------------</td>
</tr>
<tr>
<td>18:00</td>
<td>Plenary Lecture - Cancer epigenetics- Genes &amp; drugs</td>
</tr>
<tr>
<td>20:00</td>
<td>Social Activity</td>
</tr>
<tr>
<td>17:00</td>
<td>O1. Neuropharmacology I</td>
</tr>
<tr>
<td>17:00</td>
<td>O2. Cardiovascular &amp; Smooth Muscle</td>
</tr>
<tr>
<td>17:00</td>
<td>O3. Receptors &amp; Ion Channels</td>
</tr>
<tr>
<td>17:00</td>
<td>O4. Cancer, Pharmacogenomics &amp; Toxicology</td>
</tr>
<tr>
<td>17:15</td>
<td>Black Swiss Mice: molecular alterations related to mania-like behavior</td>
</tr>
<tr>
<td>17:30</td>
<td>Signaling of the fractalkine receptor CX3CR1 and its natural genetic variants: impact of receptor non-synonymous single nucleotide polymorphisms. Garcia-Silva, A. (Spain)</td>
</tr>
<tr>
<td>17:30</td>
<td>Pharmacogenomic Alerts in an Electronic Medical History. Simonovich, V. (Argentina)</td>
</tr>
<tr>
<td>18:00</td>
<td>α2A- and α2C-Adrenoceptors as Significant Targets for Dopamine and Dopamine Receptor Ligands. Casadó-Anguera, V. (Spain)</td>
</tr>
<tr>
<td>18:00</td>
<td>Rett-like severe encephalopathy caused by a de novo GRIN2B mutation is attenuated by D-serine dietary supplement. Altafaj, X. (Spain)</td>
</tr>
<tr>
<td>18:00</td>
<td>Plenary Lecture</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>08:30</td>
<td><strong>Plenary Lecture</strong> - A novel pharmacological paradigm for chronic pain. Antonio Ferrer-Montiel (Spain)</td>
</tr>
<tr>
<td>09:30</td>
<td></td>
</tr>
<tr>
<td>11:00 - 13:00</td>
<td><strong>Symposia</strong>&lt;br&gt;Room: Gran Salon Mediterranea</td>
</tr>
<tr>
<td>13:00</td>
<td>Lunch</td>
</tr>
<tr>
<td>14:30 - 16:30</td>
<td><strong>Symposia</strong>&lt;br&gt;Room: Favencia</td>
</tr>
<tr>
<td>13:00</td>
<td>Lunch</td>
</tr>
<tr>
<td>14:30 - 16:30</td>
<td><strong>Symposia</strong>&lt;br&gt;Room: Gran Salon Mediterranea</td>
</tr>
<tr>
<td>13:00</td>
<td>Lunch</td>
</tr>
<tr>
<td>14:30 - 16:30</td>
<td><strong>Symposia</strong>&lt;br&gt;Room: Sitges</td>
</tr>
<tr>
<td>13:00</td>
<td>Lunch</td>
</tr>
<tr>
<td>14:30 - 16:30</td>
<td><strong>Symposia</strong>&lt;br&gt;Room: Sitges</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>-------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>16:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>17:00</td>
<td><strong>O5. Neuropharmacology II</strong></td>
</tr>
<tr>
<td>17:15</td>
<td>The mitochondrial angiotensin II subtype-2 receptor expression declines with ageing, and modulates the catecholamine secretion in chromaffin cells” Padín-Nogueira, J.F. (Spain)</td>
</tr>
<tr>
<td>17:30</td>
<td>“The effect of buspirone on the basal ganglia output nuclei is related to the dopaminergic system integrity in rats” Vegas, S. (Spain)</td>
</tr>
<tr>
<td>17:45</td>
<td>&quot;Neuroprotective effect of novel imidazoline I2 receptor ligands in the senescence accelerated mouse prone 8 (SAMP8)&quot; Griján, C. (Spain)</td>
</tr>
<tr>
<td>18:00</td>
<td><strong>Plenary Lecture</strong> Pharmacology leaping over the gap: bringing transformational mechanisms to drug discovery. <strong>Mª Isabel Loza (Spain)</strong></td>
</tr>
</tbody>
</table>
Wednesday, June 21st

09:00 - 11:00

**S13. Neuropharmacology**

**Chairs:** Olga Valverde, Pompeu Fabra University (Spain) & Maruja Hurlé, Cantabria University (Spain)

- Vulnerability factors that predispose to cocaine addiction. *Julia García-Fuster (Spain)*
- Potential clinical value of microRNA-30c as biomarker and therapeutic target for neuropathic pain. *Monica Tramullas (Spain)*
- Behavioral and molecular alterations induced by maternal alcohol binge consumption in offspring mice. *Olga Valverde (Spain)*
- Therapeutic potential of conjugated siRNAs for the treatment of major depressive disorder. *Francisco Artigas (Spain)*

**Room:** Gran Salon Mediterranea

11:00

**Coffee Break**

11:30

**Plenary Lecture:** Present and future pharmacological treatment of Alzheimer’s disease.

*Agneata Nordberg, Karolinska Institutet, Stockholm, Sweden*

12:30

**Closing Ceremony**

13:30

**Lunch & Departure**
Posters Presentations

Moderators:
1. Amadeu Gavalda
2. Javier Meana
3. Mayte Tejerina
4. Dolores Ivorra

Neuropharmacology I

(P-1) Long-term consequences of treating rats with cocaine at a window of adolescent vulnerability on negative affect in adulthood. García-Fuster, M.J. (Spain)

(P-2) Dopaminergic degeneration partially modifies the response of the locus coeruleus to noxious stimulus. Paredes, E. (Spain)

(P-3) Brain specific carnitine palmitoyltransferase 1C (CPT1C) is involved in the hypothalamic regulation of thermogenesis by endocannabinoids-dependent mechanisms. Rodríguez-Rodríguez, R. (Spain)

(P-4) Association of regulatory TPH2 polymorphisms with higher reduction in depressive symptoms in children and adolescents treated with fluoxetine. Torres, T. (Spain)

(P-5) Chronic Δ9-THC administration leads to functional 5HT2A receptors supersensitivity mediated by inhibitory Gi/o proteins in mouse brain cortex. Ibarra, I. (Spain)

(P-6) α2A- and α2C-adrenoceptor subtypes expression in postmortem prefrontal cortex of subjects with schizophrenia. Brocos, I. (Spain)

(P-7) Ketamine-induced hypnosis in mice regulates FADD and MEK-ERK signaling in brain cortex. Salort, G. (Spain)

(P-8) Serotonin 5-HT3 receptor antagonism potentiates the antidepressant activity of citalopram. Perez del Palomar, B. (Spain)

(P-9) The use of Licochalcone A as pre-emptive pharmacological inhibition of JNK1, leads to neuronal protection against excitotoxic insults derived of kainic acid. Buquets, O. (Spain)

(P-10) Early exposure of mice to MDPV increases the vulnerability to cocaine in the adulthood. Lopez-Arnau, R. (Spain)

(P-11) Long-term consequences of treating rats with methamphetamine at a window of vulnerability during young adulthood on hippocampal cell damage. Bis-Humbert, C. (Spain)

(P-12) Repeated electroconvulsive shock increased newly born generated cells and neuroplasticity markers in the rat hippocampus. Garcia-Cabreroiz, R. (Spain)

(P-13) Acute treatment with 8-OH-DPAT improves cognition in rats by changing the strategy used to resolve a maze at different ages. Hernández-Hernández, E. (Spain)

(P-14) Black Swiss Mice: molecular alterations related to mania-like behavior. Cortes, E. (Spain)

(P-15) Actions of lithium treatment on oxidative stress markers in mitochondrial complex I and complex III inhibition and after CO2 exposure in SH-SY5Y cells. Martinez, A. (Spain)

(P-16) Resveratrol protects C57BL/6J aged mice in front of LPS acute inflammatory insult. Canudas, A.M. (Spain)

(P-17) Dual-specificity Phosphatase Dusp6 Regulates Long-Term Memory and Erk/MAP-Kinase Signaling in Hippocampus. Sindreu, C. (Spain)

(P-18) Environmental enrichment in the absence of physical exercise produces beneficial behavioural effects and anti-oxidative effects in rats. Mármol, F. (Spain)

(P-19) Gender differences on the effects of prenatal stress and perinatal diet on the behavioral profile of aged rats. Ramirez, M.J. (Spain)
Cardiovascular & Smooth Muscle

(P-22) MARCKS regulates vascular contractility. Jahan, K.S. (UK)

(P-23) Involvement of endoplasmic reticulum stress and mitochondrial dysfunction in abdominal aortic aneurysm disease. Galán, M. (Spain)

(P-24) High-fat feeding promotes dysfunction of perivascular adipose tissue. Kennedy, S. (UK)


(P-26) Electrophysiological characterization of two novel KCNK3 (TASK-1) mutations indicated in Pulmonary Arterial Hypertension. Cunningham, K. (UK)

(P-27) Chondroitin sulfate and glucosamine combination treatment for musculoskeletal diseases and osteoarthritis: a chance to kill two birds with one stone? Results in a rat-injury model. Montell, L. (Spain)

(P-28) HIV transgene expression induces endothelial dysfunction and Kv7 channel impairment in the pulmonary vasculature. Cogolludo, A. (Spain)

(P-29) MiR-1 impairs endothelial and Kv channel function in pulmonary arteries. Cogolludo, A. (Spain)

(P-30) Selenosugars are a promising class of selenium derivatives with vasculo-protective effects. Onetti, Y. (Spain)

(P-31) Increased contractile responses to phenylephrine in the ascending aorta of a murine model of Marfan syndrome reveal regional and sex differences. Jiménez-Altayó, F. (Spain)

(P-32) Lupalbigenin, a prenylated isoflavone in Derris scanden extracts, lacks vasodilator activity in the porcine isolated splenic artery. Watanapokasin, R. (Thailand)

(P-33) Endothelium-derived hyperpolarization (edh)-induced relaxation of renal arteries: role of H2O2. Rivera de los Arcos, L. (Spain)

(P-34) Role of mitogen-activated protein kinase (mapk) in the regulation of l-type channel calcium entry in resistance arteries. Gutierrez Cruz, A. (Spain)

(P-35) NADPH oxidase-derived H2O2 is involved in the endothelium-dependent relaxations of intrarenal arteries. Prieto, D. (Spain)

(P-36) Optical control of muscarinic acetylcholine receptors using photoswitchable bitopic ligands. Riefolo, F. (Spain)

(P-37) Lactobacillus fermentum CECT5716 consumption protects kidney and improves endothelial dysfunction in murine lupus. Duarte, J.M. (Spain)


(P-39) Pomace olive oil enriched in oleanolic acid restores vascular dysfunction and metabolic parameters in mice fed a high fat diet. Claro, C. (Spain)

(P-40) Decreased Expression of ETS-2 in EPCs as an Early Marker of Cardiovascular Instability in CABG Patients, Beneficial Effects of Sitagliptin. Tejerina, T. (Spain)

(P-41) Effect of the probiotic Lactobacillus fermentum CECT5716 in hypertensive rat induced by chronic nitric oxide blockade. Romero, M. (Spain)

(P-42) Hypoxic preconditioning increases the potential of exosomes derived from mesenchymal stem cells to limit pulmonary vascular dysfunction induced by lipopolysaccharide. Moreno, L. (Spain)

(P-43) PGE2 derived from MPGES-1 facilities excessive aldosterone production from adipose tissue in obesity. Role in vascular function. Briones, A.M. (Spain)

(P-44) Gut microbiota controls arterial blood pressure in rats by altering gut-brain-bone marrow interaction. Toral, M. (Spain)

(P-45) Protective effects of PPARβ/δ activation on endothelial dysfunction induced by plasma from lupus patients: Role of endoplasmic reticulum stress. Sánchez, M. (Spain)

(P-46) Changes in the expression of the NT-3/TrkC pathway in vessels and left ventricle during culture. D’Ocon, P. (Spain)

(P-47) Neurotrophin-3 and TrkC expression in blood vessels and left ventricle of adult rodents. Ivorra, M.D. (Spain)

(P-48) Pharmacological and genetic dissection of the role of TRPA1 and TRPM8 channels in intrinsic vascular responses to cold. Alonso, L. (Belgium)
Receptors & Ion Channels

(P-53) CaV2.2 (N-type) voltage-gated calcium channels are activated by SUMO-1 protein. Stephens, G. (UK)

(P-54) Modeling human bipolar disorder: The HINT1-deficient mice. Rodríguez, M. (Spain)

(P-55) The Parkinson’s disease-associated GPR37 receptor is an adenosine A2A receptor repressor in mice. Morató, X. (Spain)

(P-56) Characterisation of the actions of the novel P2Y2 receptor antagonist, AR-C118925XX. Muoboghare, M. (UK)

(P-57) Optical control of locomotor activity in a mouse model of parkinsonism using a photoactive adenosine A2A receptor antagonist. Taura, J. (Spain)


(P-59) Optical control of endogenous receptors and cellular excitability using targeted covalent photoswitches. Garrido, A. (Spain)

(P-60) Rett-like severe encephalopathy caused by a de novo GRIN2B mutation is attenuated by D-serine dietary supplement. Altafaj, X. (Spain)

(P-61) Signaling of the fractalkine receptor CX3CR1 and its natural genetic variants: impact of receptor non-synonymous single nucleotide polymorphisms. García Silva, A. (Spain)

(P-62) Glibenclamide inhibits ATP-sensitive K currents in the Cantú Syndrome. Caballero, R. (Spain)

(P-63) Cellular biology of human cardiac Nav1.5-Kir2.1 channel complexes. Caballero, R. (Spain)

(P-64) The p.P888L SAP97 polymorphism shortens the cardiac action potential duration and the QT interval. Delpón, E.

(P-65) A mutation in the Tbx5 transcription factor decreases the human cardiac sodium current and is associated with the Brugada Syndrome. Delpón, E. (Spain)

(P-66) Histochemical and functional evidence of metabotropic glutamate 5 receptor existence in brain dopaminergic neurons, with modeling of receptor interactions. Ortiz, J. (Spain)


(P-68) Pharmacological and biophysical properties of plasma membrane pores induced by silica nanoparticles. Sanchez, A. (Belgium)

(P-69) Functional μ-Opioid-galanin receptor heteromers in the ventral tegmental area. Moreno, E. (Spain)

(P-70) Specific chemical sensitivities of Drosophila melanogaster TRPA1 isoforms. Brett, B. (Belgium)

(P-71) Contactin-associated protein 1 interacts with metabotropic glutamate receptor type 5 and modulates its function in the hippocampus. Ciruela, F. (Spain)

(P-72) The large conductance, Ca2+-activated K+ channel opener VSN16R modulates hippocampal CA1 pyramidal neuron firing. Stephens, G. (UK)

Cancer

(P-73) Effect of Sideritis hyssopifolia on apoptosis in human prostate cancer LNCaP cells. García, J.J. (Spain)

(P-74) Effect of Sideritis hyssopifolia on cell cycle distribution in human prostate cancer LNCaP cells. Huerga, V. (Spain)

(P-75) Actinic keratosis: standard compounds validation in both in vitro and in vivo models. Armengol, C. (Spain)

(P-76) Synthesis and Biological evaluation of novel inhibitors of Signal Transducer and Activator of Transcription (STAT) proteins in hematological malignances. Guerra, B. (Spain)

(P-77) Identification of differential kinase off-targets among clinical PARP inhibitors: new opportunities for precision oncology? Antolín, A. (UK)

(P-78) The role of receptor protein tyrosine phosphatase beta/zeta in cell migration. Papadimitriou, E. (Greece)

(P-79) The prognostic value of the melanogenic system-based ASMT: CYP1B1 index in solid tumors. Kinker, G. (Brazil)

(P-80) Nimotuzumab and radiotherapy in the treatment of pediatric patients with diffuse intrinsic brain astrocytomas. Marrero, M.A. (Cuba)
Pharmacogenomics & Toxicology

(P-81) Host characteristics, pharmacological properties and their interactions influence type of liver injury in hepatotoxicity. Sanabria, J. (Spain)

(P-82) Drug induced liver injury assessment: acute hepatitis due to hepatitis e virus, a diagnosis to consider. Sanabria, J. (Spain)

(P-83) Prospective drug-induced liver injury registry: clinical characteristics and outcomes of 915 cases. Sanabria, J. (Spain)

(P-84) Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine. Gassó, P. (Spain)

(P-85) Prevalence of ugt1a1 genetic variants in Argentinean population, potential implications for pharmacogenomic testing. Scibona, P. (Argentina)

(P-86) Pharmacogenomic alerts in an Electronic Medical History. Simonovich, V. (Argentina)

(P-87) Pharmacogenetic study focused on fluoxetine pharmacodynamics in children and adolescent patients: Impact of the serotonin pathway. Rodríguez, N. (Spain)

(P-88) Prevalence and Pattern of Potentially Inappropriate Medication in Older Primary Care Patients. Prominent role of benzodiazepines. Blanco, E. (Spain)

TUESDAY, JUNE 20TH

Moderators:

1. Juan Carlos Leza
2. Carmen Terencio
3. Silvia Sanchez
4. Lidia Giménez

Neuropharmacology II

(P-89) The fifth subunit modulates the function of canonical agonist sites in α4β2 nicotinic receptors. García del Villar, S. (UK)

(P-90) Synthesis of new 1-substituted isoquinolines with potential anti-Parkinson activity. Cabedo, N. (Spain)

(P-91) Computational approaches for the understanding of agonist efficacy in structurally and functionally complex GPCRs. Giraldo, J. (Spain)

(P-92) Neuroprotective effect of novel imidazoline I2 receptor ligands in the senescence accelerated mouse prone 8 (SAMP8). Griñan, C. (Spain)

(P-93) Unravelling the contribution of adenosine A2A receptor to the neurobiology of schizophrenia. Valle, M. (Spain)

(P-94) Interleukin-1 receptor antagonist (IL-1ra) and brain endocannabinoids crosstalk to control neurogenesis. Molina-Holgado, F. (UK)

(P-95) In vivo photomodulation of GABA and glycine receptor channels. Gomila, A. (Spain)

(P-96) Study of the effect of early postnatal administration of a NMDA receptor antagonist in mouse on different functional and neuromorphological schizophrenic phenotypes. García, S. (Spain)

(P-97) Gene-based association analysis of gene networks for the study of extrapyramidal symptoms induced by antipsychotics. Boloc, D. (Spain)

(P-98) Identification of pharmacological chaperones for the cellular prion protein by dynamic mass redistribution screening. Iglesias, A. (Spain)

(P-99) Phosphorylation of ionotropic glutamate receptors is altered in synaptopathy conditions. Gomez de Salazar, M. (Spain)

(P-100) Effect of fingolimod phosphate on neuronal oxidative stress produced by menadione. Pavia, J. (Spain)

(P-101) HDACs and SIRT2: epigenetic targets for antidepressant therapy. Tordera, R. (Spain)

(P-102) Novel coumarins derivatives as selective MAO-B inhibitors: in vitro, in vivo and ex vivo assays. Rodriguez, F. (Spain)

(P-103) Behavioural effects of novel multitarget anticholinesterasic derivatives in aging and Alzheimer’s disease: Studies in 3xTg-AD mice. Giménez, L. (Spain)
(P-104) The effect of buspirone on the basal ganglia output nuclei is related to the dopaminergic system integrity in rats. Vegas, S. (Spain)

(P-105) Pharmacological modulation of calcium signalling and exocytosis in chromaffin cells from C57BL6/J mice. Martínez Ramírez, C. (Spain)

(P-106) Synthetic sulfatide-like sulfoglycolipids as potential neuroprotectors in brain damage. García Alvarado, F. (Spain)

(P-107) Exocytosis and mitochondrial ultrastructure and function in chromaffin cells of the SOD1G93A mouse model of ALS at a pre-disease stage. Mendez, I. (Spain)

(P-108) The mitochondrial angiotensin II subtype-2 receptor expression declines with ageing, and modulates the catecholamine secretion in chromaffin cells. Padín- Nogueira, I.F. (Spain)

(P-109) Effect of abcb1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants. Saiz, M. (Spain)

**Inflammation**

(P-110) Suppressor of cytokine signalling 3 (SOCS3) interactions with cavin-1 links SOCS3 function and cavin-1 stability. Lewis, J.J. (UK)

(P-111) Prostanoid-mediated inhibition of IL-6 trans-signalling in pulmonary arterial hypertension: A role for EPAC-1 mediated Induction of “suppressor of cytokine signalling 3” (SOCS3). Durham, G. (UK)

(P-112) Oleuropein exhibited anti-inflammatory and anti-oxidant activities in IL-1β&#946;-stimulated human synovial fibroblasts. Castejón, M.L. (Spain)

(P-113) Hydroxytyrosol derivative modulates inflammatory response in LPS- induced murine peritoneal macrophages. Montoya, T. (Spain)

(P-114) VLDL and apolipoprotein ciii induce stress and inflammation and attenuate insulin signaling via toll-like receptor 2 and erk1/2 in skeletal muscle cells. Vazquez- Carrera, M. (Spain)

(P-115) Characterization of the in vitro and in vivo profile of Epigallocatechin-3-gallate. Carreño, C. (Spain)


(P-117) EVOO phenols, hydroxytyrosol and hydroxytyrosol acetate, supressed IL-1β&#946;-induced proinflammatory mediators production in human synovial fibroblasts. Rosillo, M.A. (Spain)

(P-118) Chondroitin sulfate inhibits monocyte chemotractant protein-1 release from 3T3-L1 adipocytes: a new treatment opportunity for obesity-related metabolic syndromes? Montell, L. (Spain)

(P-119) CX3CL1/CX3CR1 and CCL2/CCR2 axes are potential therapeutic targets to prevent arterial leukocyte adhesion in metabolic syndrome. Gomes, P. (Spain)

(P-120) A Fluoromethychalcone derivative as inhibitor of caspase-1 activation in CPPD-induced Mouse Air Pouch model. Catalán, L. (Spain)

(P-121) Anti-inflammatory and immunomodulatory effects of osteostatin in the CIA model. Nacher, J. (Spain)

(P-122) ORM2 and APOA2 serum levels can predict the patient response to chondroitin sulfate/glucosamine hydrochloride: results from the moves study. Martínez, H. (Spain)

(P-123) The Angiotensin-(1-7)/ Mas Receptor Axis Counteract Pro-Inflammatory Signaling in Human Vascular Smooth Muscle Cells. Romero, A. (Spain)

(P-124) Beneficial effect of adenosine A2B receptor activation in a murine model of skin hyperplasia. Terencio, M.C. (Spain)

(P-125) IKKα is involved in pro-inflammatory activity of extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in bone marrow-derived macrophages. Bermúdez, B. (Spain)

(P-126) Discovery of Small Molecules for IL-17 Mediated Inflammatory Diseases. Álvarez, E. (Spain)

(P-127) Vascular damage induced by visfatin in mice involves NADPH oxidase activation and prostanoid release. Ramos, M. (Spain)

(P-128) Psoriatic fibroblasts polarize macrophages to a pro-inflammatory phenotype. Montesinos, M.C. (Spain)

**Natural Products**

(P-129) Effect of the intake of the strain Bifidobacterium animalism subsp. lactis CECT 8145 in Zucker fatty rats. Aleixandre, M.A. (Spain)

(P-130) Effects of pepsin egg white hydrolysate on metabolic syndrome. Miguel, M. (Spain)

(P-131) Topical pre-treatment with a carotenoid from microalgae reduces cutaneous UVB-induced inflammation in hairless mice.
Rodríguez, A. (Spain)

(P-132) Diosmetine and diosmine inhibit the pro-inflammatory cytokines release. Zaragozá, C. (Spain)

(P-133) Anti-inflammatory and sedative activities of peperomia galioides: in vivo studies in mice. Vila, E. (Spain)

(P-134) Hepatoprotective effect of croton hypoleucus following thioacetamide-induced necrosis in rats. Urrutia, T. A. (Mexico)

(P-135) The reduction in adrenergic and inflammatory serum markers in osteoarthritis patients after treatment with chondroitin sulfate/glucosamine hydrochloride and celecoxib is different according to the presence of bacterial DNA in blood. Martínez, H. (Spain)

(P-136) Safety study on the use of medicinal plants. Gruszcyki, M. (Argentina)

(P-137) Hemp (cannabis sativa L.) seed oil as a source of bioactive compounds for the treatment of fibromyalgia-related symptoms. Montserrat-de la Paz, S. (Spain)

(P-138) Dual effects of resveratrol on cell death and proliferation of colon cancer cells. San Hipólito, A. (Spain)

(P-139) Effects of olive leaf extract in high-fat diet-fed mice: impact on vascular dysfunction. Díez, P. (Spain)

(P-140) Anthelmintic activity of essential oils against Anisakis simplex L3 larvae. López, V. (Spain)

(P-141) Antioxidant and bioactive properties of Jasion glutinosa (Compositae) in caenorhabditis elegans. López, V. (Spain)

Teaching Pharmacology

(P-142) Active Learning: Alignment of Assessment and Objectives. Patangi, R. (Canada)

(P-143) Motivational tools to encourage students to become engaged in a pharmacology subject. García, J.J. (Spain)

(P-144) Rubric-based scoring in a hands-on session of Veterinary Pharmacology. Huerga, V. (Spain)

(P-145) Does the design and development of objective structured clinical examinations by undergraduate students of Podiatry degree improve their learning and assessment skills about medicines? Bellido, I. (Spain)

(P-146) The last frontier: Inter professional learning events between dentistry and pharmacy. Durham, L. (UK)

(P-147) Using cinema films as an innovative educational strategy to create meaningful learning in pharmacology teaching. Cabanillas, A. (Chile)

(P-148) Implementation and evaluation of an online self-assessment system to improve student performance in Pharmacology. Moreno, L. (Spain)

(P-149) Students of the Primary Education Degree, as the new player in health and nutrition promotion. Bermudez, B. (Spain)

(P-150) New academic perspectives in teaching pharmacology and clinical therapeutics: an international service learning experience. Lucena, M. (Spain)

(P-151) Attractive key historical facts as a tool to teach pharmacology. Serés, E. (Spain)

(P-152) How did the press approach the discovery and use of sulphonamides during the 20th century? Serés, E. (Spain)

(P-153) Rational Pharmacotherapy in the assessment of clinical competence using an Objective Structured Clinical Examination “OSCE”. Blanco, E. (Spain)

(P-154) Preparing pharmacy students to practice: specialized reports and oral communication activities. Recio, M.C. (Spain)

(P-155) Peer instruction in veterinary pharmacology: a preliminary experience. Clos, V. (Spain)

Pain

(P-156) Postoperative pain and morphine consumption after ultrasound-guided femoral and sciatic combined nerve block versus neurostimulation for femoral and sciatic combined nerve block or neurostimulation for femoral nerve block in primary elective total KN. Bellido, I. (Spain)

(P-157) sensitization of trpv1 neurons by pge2: Lost of sensory selectivity for noxious heat and participation on mechanical hyperalgesia. Ruiz, M.C. (Spain)

(P-158) Activation of extracellular signal-regulated kinases (ERK 1/2) in the Locus Coerulesus contributes to pain-related anxiety in arthritic rats. Da Silva, G. (Spain)

(P-159) Treatment with sulforaphane enhances the antinociceptive effects of delta opioid receptors in diabetic mice: mechanisms implicated. Pol, O. (Spain)

(P-160) Epigenetic mechanisms underlying neuropathic pain in rats. Francés, R. (Spain)

(P-161) The chemokine CCL4 induces opioid analgesia through lymphocyte stimulation and inhibits inflammatory hyperalgesia in mice. García, M. (Spain)
Effects of vascular endothelial growth factor-A165b and SRPK1 inhibition in the monosodium iodoacetate model of osteoarthritis in rat. Almahasneh, F. (UK)

Treatment of neuropathic pain associated to the spared nerve injury model in mice: role of sigma-1 receptors. Bravo, I. (Spain)

Development of phenotypic in vitro models of pain in early drug discovery. Martinez, A.L. (Spain)

Ischemia & Reperfusion

Simvastatin blocks soluble SSAO/VAP-1 release in experimental models of cerebral ischemia: possible benefits for stroke-induced inflammation control. Unzeta, M. (Spain)

Plasma levels of therapeutic drugs significantly inhibit blood-brain barrier endothelial cell ABC transporters. Shubbar, M. (UK)

Impact of cerebral ischemia/reperfusion and uric acid treatment on middle cerebral artery angiogenesis in normotensive and spontaneously hypertensive rats. Masip, M. (Spain)

Gastrointestinal

New curcumin-coumarin derivatives and resveratrol reduce patophysiological processes associated with pancreatitis and pancreatic cancer. Bugallo, A.I. (Spain)

Olive Leaf extract exhibits immunomodulatory activity in human PBMCS and Anti-Inflammatory effect in the DSS model of mouse colitis. Vezza, T. (Spain)